Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J05AR01

Combivir(lamivudine;zidovudine)

HIV Infections

Marketing Authorisation Holder: ViiV Healthcare BV

EMA Authorisation: 18/03/1998

INN: lamivudine;zidovudine

Indication

Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Combivir — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.